Senti Biosciences Holdings (SNTI) Profit After Tax (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Profit After Tax of -$14.5 million for Q4 2025, down 2233.39% year-over-year from $678123.5 in Q4 2024, and up 20.19% quarter-over-quarter from -$18.1 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Profit After Tax (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Profit After Tax history runs 5 years deep, the most recent figure standing at -$14.5 million for Q4 2025.
- In Q4 2025, Profit After Tax fell 2233.39% year-over-year to -$14.5 million; the TTM figure through Dec 2025 stood at -$61.4 million (down 16.36% YoY), while the FY2025 annual figure was -$61.4 million, down 16.36% from the prior year.
- Profit After Tax for Q4 2025 stood at -$14.5 million, up from -$18.1 million in the prior quarter.
- The five-year high for Profit After Tax was -$620000.0 in Q4 2024, with the low at -$71.1 million in Q4 2023.
- The 5-year median for Profit After Tax is -$14.6 million (2025), against an average of -$18.8 million.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 99.13% in 2024, then sank 2233.39% in 2025.
- Senti Biosciences Holdings' Profit After Tax stood at -$3.9 million in 2021, then slumped by 1187.63% to -$49.7 million in 2022, then plunged by 43.07% to -$71.1 million in 2023, then jumped by 99.13% to -$620000.0 in 2024, then tumbled by 2233.39% to -$14.5 million in 2025.
- Business Quant data shows SNTI's Profit After Tax at -$14.5 million in Q4 2025, -$18.1 million in Q3 2025, and -$14.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | -12.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14.47 Mn |
| Sep 30, 2025 | -18.13 Mn |
| Jun 30, 2025 | -14.73 Mn |
| Mar 31, 2025 | -14.11 Mn |
| Dec 31, 2024 | -620,000.00 |
| Sep 30, 2024 | -28.87 Mn |
| Jun 30, 2024 | -11.20 Mn |
| Mar 31, 2024 | -12.11 Mn |
| Dec 31, 2023 | -71.06 Mn |
| Sep 30, 2023 | -14.92 Mn |
| Jun 30, 2023 | -18.70 Mn |
| Mar 31, 2023 | -18.72 Mn |
| Dec 31, 2022 | -49.67 Mn |
| Sep 30, 2022 | -16.64 Mn |
| Jun 30, 2022 | -11.55 Mn |
| Mar 31, 2022 | -11.81 Mn |
| Dec 31, 2021 | -3.86 Mn |
| Sep 30, 2021 | -11.41 Mn |
| Jun 30, 2021 | -12.01 Mn |
| Mar 31, 2021 | -21.00 Mn |